On October 15, 2022, MAPS released a progress report for Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous progress reports were released for quarters ending in January, April, and July. …
On August 30, 2022, the FDA responded to MAPS’ request to lift the clinical hold placed on our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2), citing an incomplete response to the hold. …
On August 16, 2022, MAPS submitted a complete response to the FDA addressing the continued partial clinical hold letter, received on December 27, 2021.
On July 21, 2022, a general medical and psychiatric practice in Steinheim, Germany, released a statement about their use of cannabis to treat patients with symptoms of posttraumatic stress disorder (PTSD). …
On July 15, 2022, MAPS released a grant progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). Previous grant reports were released in January and April. Read the July 2022 grant …
Study MJP2 protocol was initially submitted on March 9, 2021. The study was put on hold by FDA on May 10, 2021 with additional comments for the hold provided on June 3, 2021. MAPS provided FDA with a response …
On April 15, 2022, MAPS wrote the second progress report for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The first report was for the reporting period ending January 15, 2022. Read the …
Highlights A randomized, placebo-controlled, Phase 3 trial demonstrated the safety and efficacy of MDMA-assisted therapy for the treatment of severe posttraumatic stress disorder (PTSD) Participants met …
On January 14, 2022, MAPS released the first MRA VMR Grant Update for the reporting period ending January 15, 2022 for our Phase 2 Study of Cannabis for Veterans with PTSD (MJP2). The quarterly performance …
MAPS) has been awarded a $12,979,050 grant from Michigan’s $20 million competitive 2021 Veteran Marijuana Research Grant Program. The program, which is funded by adult-use marijuana retail taxes, is …
We’ve finally reached the point where we can shout our good news from the roof tops and publicly celebrate the work of this amazing team! The publication of our MAPP1 findings is official as of this …
The highly statistically significant results and excellent safety record suggest MDMA-assisted therapy will be approved as effective treatment for severe, chronic PTSD in 2023. 67% of participants who …
